DB08888 - Ocriplasmin
| Identification | |
|---|---|
| Name | Ocriplasmin |
| Accession Number | DB08888 |
| Type | biotech |
| Description | Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012. |
| Structure |
|
| Categories (*) | |
| Molecular Weight | 27.25 kDa |
| Groups | approved |
| Monoisotopic Weight | Not Available |
| Pharmacology | |
| Indication | Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion. |
| Mechanism of action | Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA). |
| Absorption | Because of the small dose administered (0.125 mg), ocriplasmin is not expected to be in the systemic circulation following injection. Within 30 minutes after injection, levels of ocriplasmin in the vitreous are 12 mcg/mL. 24 hours after injection, levels in the virtreous are 0.5 mcg/mL |
| Protein binding | Not Available |
| Biotransformation | Ocriplasmin is quickly inactivated by protease inhibitor ?2-antiplasmin or ?2-macroglobulin. |
| Route of elimination | Not Available |
| Toxicity | The most commonly reported reactions (>= 5%) in patients treated with ocriplasmin were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema. |
| Affected organisms |
|
| Interactions | |
| Drug Interactions | Not Available |
| Food Interactions | Not Available |
Targets
| Fibronectin | |
|---|---|
| Name | Fibronectin |
| Gene Name | FN1 |
| Pharmacological action | yes |
| Actions | cleavage |
| References |
|
| DTHybrid score | 1.4692 |
| Alpha-2-macroglobulin | |
| Name | Alpha-2-macroglobulin |
| Gene Name | A2M |
| Pharmacological action | no |
| Actions | ligand |
| References | |
| DTHybrid score | 1.6882 |
| Alpha-2-antiplasmin | |
| Name | Alpha-2-antiplasmin |
| Gene Name | SERPINF2 |
| Pharmacological action | no |
| Actions | ligand |
| References | |
| DTHybrid score | 1.4693 |
Predictions
| Id | Partner name | Gene Name | Score |
|---|---|---|---|
| 2155 | Insulin-degrading enzyme | IDE | 0.2835 |
| 950 | Alpha platelet-derived growth factor receptor | PDGFRA | 0.1465 |
| 228 | Beta platelet-derived growth factor receptor | PDGFRB | 0.1415 |